Study of DONQ52 in Active Celiac Disease

Summary

The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.

Timeline

Start

2025-12-16

Primary completion

2027-06-15

Completion

2027-12-15

Drugs

Indications